Are These Top Health Care Stocks On Your Radar This Week?
There’s no doubt that health care stocks are some of the more popular sectors to watch right now. Sure, companies that have their hands on potential vaccines or treatments could be more attractive to some. But the thing is, healthcare companies that are developing immunotherapies for other diseases aren’t showing signs of slowing down too. New cancer drugs, potential treatments for novel diseases, and even companies that specialize in specific medical equipment are the reasons why investors are looking for up and coming health care stocks to buy.
Large-cap healthcare or pharmaceutical stocks have a more solid pipeline of drugs under their belt. But they couldn’t provide huge upside like the small-cap healthcare stocks. Something to keep in mind, however, is that small-cap healthcare stocks are generally riskier. And these smaller cap stocks are usually more suitable for traders looking for a quick flip when the momentum is still hot. And for these up and coming healthcare stocks, they usually have a niche on their own, focusing on a specific treatment.
After all, most companies started as small-cap stocks before taking off. Look at Novavax (NVAX Stock Report). If you haven’t been following the healthcare space, that was a penny stock under $5 beginning of this year. And now it is trading at $140 per share after massive breakouts. That’s the advantage of being early in an early-stage healthcare/biotech company. Investors win big when the companies they bet on the win the approval from FDA for specific drugs they are about to offer. When you mix both early-stage healthcare stock with a small-cap stock, the risk and volatility are magnified. Investors are advised to tread carefully if this area of the stock market is of interest to you.
- When Will Airline Stocks Recover?
- JetBlue And American Airlines Team Up; What’s This Mean For Airline Stocks In 2020?
- 2 Top Cloud Stocks To Buy Or Sell Right Now?
Top Healthcare Stocks To Buy Right Now [Or Avoid]: Owens & Minor
Owens & Minor (OMI Stock Report) isn’t exactly a healthcare company. But rather it is a healthcare services company. OMI stocks were skyrocketing on Tuesday and closed 82% higher. The huge jump came after OMI provided a preliminary second-quarter update that surpassed analysts’ expectations. The company benefited hugely from the unprecedented demand for personal protective equipment (PPE), favorable product mix, and operating efficiencies. Perhaps more importantly, earlier than expected elective procedures across the country translate to higher sales for many of the company’s products.
Owens & Minor is scheduled to report its second-quarter results on 4th August. The following update might not be as big of a catalyst for OMI stock as it would have otherwise been after the company’s preliminary report today. Nonetheless, OMI stocks are now up more than 160% year to date. And investors couldn’t be happier with the stock performances. We won’t discount the possibility for a longer rally. Considering the fact that the pandemic is unlikely to go away anytime soon, could OMI stock be poised for strong growth in the coming quarters?
[Read More] Uber Vs Lyft: Which Tech Stock Will Win The Race?
Top Healthcare Stocks To Buy Right Now [Or Avoid]: Midatech Pharma
Midatech Pharma (MTP Stock Report) is one of the best stocks to buy this week. The company said it will be taking part in a research collaboration on the Q-Sphera with a European affiliate with a global company. As a result, MTP stocks closed 152% higher during Tuesday’s trading session. The company focuses on the R&D of oncology and rare disease products in the U.K., the rest of Europe, and internationally. The company is currently developing MTD201, a long-acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma.
“This collaboration with a highly reputable company further builds upon Midatech’s mission to use our expertise and established capabilities to continually innovate and improve our technologies. By furthering our collaborative business model, we believe we can enable the unique qualities of this technology to reach beyond our own internal development pipeline for the benefit of all patients.”- Stephen Stamp, CEO Midatech Pharma
Right now, all we know is that it’s a “highly reputable” company. What we also do know is that BlackRock Inc. has a certain stake in the company. Moving forward, it will be interesting to watch when these details emerge further. For these reasons, it could be interesting to include MTP stocks onto a list of top healthcare stocks to buy for the near-term